What is Indapta Therapeutics?
Founded in 2017, Indapta Therapeutics operates at the intersection of biotechnology and advanced immunology. The company is dedicated to addressing the unmet medical needs of patients suffering from blood cancers, solid-tumor malignancies, and various autoimmune conditions. Its core value proposition lies in a proprietary, naturally-occurring g-NK cell platform, which is engineered to provide highly potent, scalable, and accessible therapeutic solutions. By focusing on the scalability of cell-based interventions, Indapta distinguishes itself from traditional therapeutic approaches, aiming to redefine the standard of care through precision medicine and innovative biological engineering.
How much funding has Indapta Therapeutics raised?
Indapta Therapeutics has raised a total of $123.3M across 3 funding rounds:
Series A
$50M
Other Financing Round
$22.5M
Private Equity
$50.8M
Series A (2022): $50M with participation from Vertex Ventures, Leaps by Bayer, Myeloma Investment Fund, and RA Capital Management
Other Financing Round (2024): $22.5M led by Bayer, Vertex Ventures HC, and RA Capital Management
Private Equity (2025): $50.8M, investors not publicly disclosed
Key Investors in Indapta Therapeutics
Bayer
Bayer is a global enterprise in the life science fields of healthcare and nutrition, supporting efforts to overcome major challenges in an aging global population.
Vertex Ventures HC
Vertex Ventures HC is a healthcare and life sciences venture capital fund that invests in biopharmaceuticals and medical devices to improve patient quality of life.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies.
What's next for Indapta Therapeutics?
With the infusion of this recent capital, Indapta Therapeutics is well-positioned to accelerate its clinical development pipeline and expand its manufacturing capabilities. The strategic focus will likely shift toward advancing its lead candidates through rigorous clinical trials while optimizing the scalability of its g-NK cell production. As the company matures, the emphasis will remain on validating the efficacy of its platform in human subjects, potentially opening doors for future partnerships or commercialization efforts. The continued support from specialized life science investors suggests a strong confidence in the firm's ability to navigate the complex regulatory and scientific hurdles inherent in the biotech sector.
See full Indapta Therapeutics company page
